.svg?iar=0&rev=04f97e5917f74dd7ba31609dd2679b85&hash=B48BFC8A4E413DB0B57E3C88497F951F){kind=logo}
/hfh-logo-main--white.svg?iar=0&rev=576e614e7a874290969b550a5935b275&hash=06AF579720DC0ECD15AAE5D6729FB49C){kind=logo}
Request Information on Clinical Trials
If you were diagnosed with a brain tumor we may have a clinical trial for you.
GBM AGILE Trial (Adaptive Global Innovative Learning Environment)
GBM AGILE (Adaptive Global Innovative Learning Environment) is a seamless clinical trial aimed at identifying the most effective therapies for patients with glioblastoma, the most aggressive form of brain cancer. Led by the trial sponsor Global Coalition for Adaptive Research (GCAR), we were the first in the world to enroll a patient in the GBM AGILE Trial.
This next-generation clinical trial program and adaptive platform trial for brain cancer moves away from the traditional, one-size-fits-all approach to clinical trials; it is a major step forward for precision medicine.
Current glioblastoma treatments have been refined — including surgery, radiation and chemotherapy — but in the era of molecular medicine, immunotherapy and targeted therapies, dramatic leaps in outcomes may be more attainable with this clinical trial.
What is the GBM AGILE difference
Traditional clinical trials:
- Take three to seven years to produce results
- Cannot be modified once started
- Study only one treatment against the standard of care
GBM AGILE changes the model by evaluating multiple therapies simultaneously to more efficiently and rapidly identify effective therapies for patients with glioblastoma. Drugs that show initial evidence of benefit to patients will seamlessly transition to a confirmatory stage designed to support drug approval. Drugs that are underperforming are dropped. The intent is to lower the cost, time, and number of patients required to evaluate potential new, effective therapies for patients with glioblastoma.
The efficiency, speed and learning of GBM AGILE allows for rapid discovery of better treatments for patients with glioblastoma.
GBM AGILE was first conceived in 2015 by an international group of more than 130 clinicians, researchers, biostatisticians, imagers, pathologists, patient advocates, and leaders from government and industry known as the “GBM Knowledge Network.”. One of the first types of tumors studied in the landmark precision medicine effort was glioblastoma. Henry Ford was a major TCGA contributor, nearly 25% of all the gliomas studied over the course of the initiative having been donated by Henry Ford’s Hermelin Brain Tumor Center.
